Nanosphere (NSPH +9.7%) gets a boost from an initiation at Canaccord with a Buy rating and a $5...

|By:, SA News Editor

Nanosphere (NSPH +9.7%) gets a boost from an initiation at Canaccord with a Buy rating and a $5 price target. Canaccord says NSPH is poised to capture a big chunk of the molecular diagnostics business after revamping its strategic approach last year ago to focus on blood stream infections. The company garnered FDA approval of its Gram-Positive Blood Culture Nucleic Acid Test in June 2012, and has become an early leader in the rapid detection of sepsis, which kills around 200K Americans annually and infects over 750K.